- Creso Pharma (CPH)’s new hemp-based lozenge product is in the final stages of development
- This product contains cannabidiol acid (CBD-A), a chemical precursor of cannabidiol (CBD), showing potential therapeutic effects.
- Early data suggest that CBD-A may block the COVID-19 virus spike protein from binding to and infecting cells.
- The company expects to get an initial sample of the product during the quarter.
- In the market, Creso fell 1.12%, trading at 8.8 cents per share.
Creso Pharma (CPH) is in the final stages of developing a new hemp-based lozenge product.
This new product is hemp flour based and contains cannabidiol acid (CBD-A), a chemical precursor to cannabidiol, demonstrating potential therapeutic effects.
Early data suggest that CBD-A may block the COVID-19 virus spike protein from binding to and infecting cells.
In particular, the company has not conducted its own research on the effectiveness of new troche products in the treatment of COVID-19.
Creso’s new products will be commercialized and marketed as food supplements in the European and Latin American markets.
The company expects to get an initial sample of the product during the quarter.
Once a new product line is established, Croesus will take steps to introduce a new delivery method transfer for consumers.
“Cressoma has a solid track record of introducing innovative new products, and we are confident that the development of this new hemp-based lozenge will be the basis for launching another powerful product range that can be sold in the international market. Said William Ray, Managing Director and CEO.
“As the CBD and hemp sectors continue to expand rapidly, Cresoma is in a good position to leverage its portfolio. Once development is complete, the company has recently acquired an existing business in Europe. We will start selling new products through our US business unit. ”
In the market, Creso fell 1.12%, trading at 8.8 cents per share at 3:30 pm AEDT.
